Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
暂无分享,去创建一个
Oliver Sartor | Susan Halabi | Lawrence H Schwartz | Walter M Stadler | Christopher Logothetis | Ethan Basch | Johann S de Bono | Andrew J Armstrong | P. Kantoff | P. Nelson | L. Schwartz | E. Basch | M. Morris | H. Scher | E. Antonarakis | A. Armstrong | C. Higano | E. Small | C. Sternberg | E. Heath | C. Logothetis | G. Wilding | M. Carducci | D. Rathkopf | P. Corn | O. Sartor | W. Stadler | R. Dreicer | D. George | D. Nanus | M. Taplin | M. Hussain | K. Fizazi | T. Beer | S. Slovin | C. Ryan | K. Chi | J. D. de Bono | S. Halabi | M. Stein | Daniel J George | Philip W Kantoff | Howard I Scher | Maha Hussain | Glenn Liu | George Wilding | Peter S Nelson | Eric J Small | Matthew R. Smith | Elisabeth I Heath | Paul G Corn | Cora N Sternberg | Michael A Carducci | Emmanuel S Antonarakis | Tomasz M Beer | Karim Fizazi | Michael J Morris | Kim N Chi | Glenn Liu | Robert Dreicer | Celestia Higano | Susan F Slovin | Mary-Ellen Taplin | Charles J Ryan | Wm Kevin Kelly | David Nanus | Mark N Stein | Dana E Rathkopf | Matthew Raymond Smith | W. Kelly
[1] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[2] P. Kantoff,et al. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[4] F. Saad,et al. Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.
[5] E. Basch,et al. Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. , 2013, Journal of oncology practice.
[6] H. Scher,et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. , 2012, European urology.
[7] F. Saad,et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] F. Saad,et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.
[9] P. Schellhammer,et al. Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen , 1993, Cancer.
[10] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[11] M. Rubin,et al. Aggressive Variants of Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.
[12] F. Saad,et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Peter Chang,et al. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. , 2014, Journal of the National Cancer Institute.
[14] K. Nakajima,et al. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases , 2013, Annals of Nuclear Medicine.
[15] I. Tannock,et al. The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. , 2014 .
[16] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[17] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[18] F. Saad,et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Stephens,et al. Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary , 2013, Clinical Cancer Research.
[20] A W Partin,et al. Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.
[21] L. Edenbrandt,et al. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). , 2014, Urologic oncology.
[22] Amy P Abernethy,et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). , 2014, Journal of the National Cancer Institute.
[23] P. Febbo,et al. Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success. , 2013, Radiology.
[24] Xiaoyu Jia,et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. , 2009, The Lancet. Oncology.
[25] Howard I. Scher,et al. Circulating Tumor Cells as Biomarkers in Prostate Cancer , 2011, Clinical Cancer Research.
[26] K. Owzar,et al. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Larson,et al. Validation and clinical utility of prostate cancer biomarkers , 2013, Nature Reviews Clinical Oncology.
[28] Elizabeth Garrett-Mayer,et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Susan Halabi,et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] B. Freidlin,et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J Bogaerts,et al. Evaluation of lymph nodes with RECIST 1.1. , 2009, European journal of cancer.
[32] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[33] F. Saad,et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.
[34] Carolyn M. Reilly,et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. , 2014, Journal of the National Cancer Institute.
[35] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[36] E. Antonarakis,et al. Association of pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with first‐line docetaxel , 2014, BJU international.
[37] K. Pienta,et al. New and emerging therapies for bone metastases in genitourinary cancers. , 2013, European urology.
[38] E. Basch,et al. Pain palliation measurement in cancer clinical trials: The US Food and Drug Administration perspective , 2014, Cancer.
[39] P. Kantoff,et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] M. Wirth,et al. Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014 .
[41] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] S. Larson,et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Tomasz Burzykowski,et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Katherine R. Edwards,et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function , 1995, Pain.
[45] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.
[46] Jonathan G Goldin,et al. Computer-aided quantitative bone scan assessment of prostate cancer treatment response , 2012, Nuclear medicine communications.
[47] A. Armstrong,et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. , 2013, Journal of the National Cancer Institute.
[48] U. S. Department of Health and Human Services FDA Cen Research,et al. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.
[49] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[50] Kevin Regan,et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] M. Carducci,et al. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. , 2015, European urology.
[52] J. Manola,et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] K. Pienta,et al. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.
[54] M. Morris,et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] W. Isaacs,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.
[56] Sylvia Janetzki,et al. Improved Endpoints for Cancer Immunotherapy Trials , 2010, Journal of the National Cancer Institute.
[57] I. Thompson,et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] M. Carducci,et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.
[59] Gregory R Pond,et al. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. , 2014, Clinical genitourinary cancer.
[60] I. Tannock,et al. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. , 2014, European urology.
[61] E. Basch,et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[62] F. Frueh,et al. Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer , 2014, Clinical Cancer Research.
[63] J. Bono,et al. Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents , 2015, British Journal of Cancer.
[64] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[65] A. Armstrong,et al. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[66] I. Tannock,et al. A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis , 2007, Clinical Cancer Research.